MX2023004341A - Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios. - Google Patents
Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.Info
- Publication number
- MX2023004341A MX2023004341A MX2023004341A MX2023004341A MX2023004341A MX 2023004341 A MX2023004341 A MX 2023004341A MX 2023004341 A MX2023004341 A MX 2023004341A MX 2023004341 A MX2023004341 A MX 2023004341A MX 2023004341 A MX2023004341 A MX 2023004341A
- Authority
- MX
- Mexico
- Prior art keywords
- nmt
- cancer
- disorders
- inhibitors
- treatment
- Prior art date
Links
- 108010016306 Glycylpeptide N-tetradecanoyltransferase Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 title abstract 2
- WKTSLVQYGBHNRV-UHFFFAOYSA-N 2,6-dichloro-n-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(2-piperazin-1-ylpyridin-4-yl)benzenesulfonamide Chemical compound CC(C)CC1=NN(C)C(C)=C1NS(=O)(=O)C1=C(Cl)C=C(C=2C=C(N=CC=2)N2CCNCC2)C=C1Cl WKTSLVQYGBHNRV-UHFFFAOYSA-N 0.000 abstract 3
- SOXNKJCQBRQUMS-UHFFFAOYSA-N 1-[5-[3,4-difluoro-2-[2-(1,3,5-trimethylpyrazol-4-yl)ethoxy]phenyl]-1-methylindazol-3-yl]-N,N-dimethylmethanamine Chemical compound CN(C)Cc1nn(C)c2ccc(cc12)-c1ccc(F)c(F)c1OCCc1c(C)nn(C)c1C SOXNKJCQBRQUMS-UHFFFAOYSA-N 0.000 abstract 2
- XMBSZPZJLPTFMV-UHFFFAOYSA-N 2,6-dichloro-4-(2-piperazin-1-ylpyridin-4-yl)-n-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide Chemical compound CC1=NN(C)C(C)=C1NS(=O)(=O)C1=C(Cl)C=C(C=2C=C(N=CC=2)N2CCNCC2)C=C1Cl XMBSZPZJLPTFMV-UHFFFAOYSA-N 0.000 abstract 2
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describe el uso de inhibidores de N-miristoil transferasa (NMT) en el tratamiento del cáncer, trastornos autoinmunes y trastornos inflamatorios. Con respecto al cáncer, el cáncer preferido a ser tratado es el linfoma de células B y el NMT utilizado es el PCLX-001 (DDD86481, CAS RN 1215011-08-07). Los inhibidores de NMT preferidos para el tratamiento de los trastornos autoinmunes e inflamatorios incluyen el PCLX-001 anteriormente mencionado, PCLX-002 (DDD85646, CAS RN 1215010-55-10) e IMP-1088 (CAS RN 2059148-82-0) y los trastornos a ser tratados incluyen la artritis reumatoide, asma, gastritis, colitis y otros padecimientos digestivos y respiratorios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093970P | 2020-10-20 | 2020-10-20 | |
| PCT/CA2021/051475 WO2022082306A1 (en) | 2020-10-20 | 2021-10-20 | Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004341A true MX2023004341A (es) | 2023-05-24 |
Family
ID=81291100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004341A MX2023004341A (es) | 2020-10-20 | 2021-10-20 | Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4232032A1 (es) |
| JP (1) | JP2023546217A (es) |
| KR (1) | KR20230092962A (es) |
| CN (1) | CN116234547A (es) |
| AU (1) | AU2021366973A1 (es) |
| CA (1) | CA3195753A1 (es) |
| IL (1) | IL302193A (es) |
| MX (1) | MX2023004341A (es) |
| WO (1) | WO2022082306A1 (es) |
| ZA (1) | ZA202304512B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023164776A1 (en) * | 2022-03-03 | 2023-09-07 | Pacylex Pharmaceuticals Inc. | Oral pclx-001 in the treatment of human cancer |
| WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2914261T3 (da) * | 2012-10-30 | 2021-03-22 | Pacylex Pharmaceuticals Inc | Syntetisk letalitet og behandling af cancer |
| GB201511382D0 (en) * | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| GB201820660D0 (en) * | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Cancer treatments |
-
2021
- 2021-10-20 WO PCT/CA2021/051475 patent/WO2022082306A1/en active Application Filing
- 2021-10-20 MX MX2023004341A patent/MX2023004341A/es unknown
- 2021-10-20 AU AU2021366973A patent/AU2021366973A1/en active Pending
- 2021-10-20 IL IL302193A patent/IL302193A/en unknown
- 2021-10-20 KR KR1020237016608A patent/KR20230092962A/ko unknown
- 2021-10-20 EP EP21881412.7A patent/EP4232032A1/en active Pending
- 2021-10-20 CN CN202180071879.7A patent/CN116234547A/zh active Pending
- 2021-10-20 JP JP2023524184A patent/JP2023546217A/ja active Pending
- 2021-10-20 CA CA3195753A patent/CA3195753A1/en active Pending
-
2023
- 2023-04-18 ZA ZA2023/04512A patent/ZA202304512B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021366973A1 (en) | 2023-05-25 |
| CN116234547A (zh) | 2023-06-06 |
| WO2022082306A1 (en) | 2022-04-28 |
| JP2023546217A (ja) | 2023-11-01 |
| IL302193A (en) | 2023-06-01 |
| ZA202304512B (en) | 2024-01-31 |
| CA3195753A1 (en) | 2022-04-28 |
| KR20230092962A (ko) | 2023-06-26 |
| EP4232032A1 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202304512B (en) | Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders | |
| MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| PH12018500322A1 (en) | Methods of treating cancer patients with farnesyltransferase inhibitors | |
| MX2020002150A (es) | Terapia de combinación para el tratamiento del cáncer. | |
| NZ595331A (en) | Ex-vivo treatment of immunological disorders with pkc-theta inhibitors | |
| PH12016500780A1 (en) | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2023014187A (es) | Un inhibidor de receptor de interleucina-4 para usarse en el tratamiento de la dermatitis atopica severa. | |
| MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
| WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
| MX2021015996A (es) | Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2). | |
| MX2016004039A (es) | Sistemas y metodos de tratamiento de agua para acuicultura. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| MX2023014565A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| MX2022004259A (es) | Inhibidores de mek para el tratamiento de infecciones por hantavirus. | |
| MX2022010093A (es) | Tafoxiparina para el tratamiento de la preeclampsia. | |
| WO2020092720A3 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| PH12019501918A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| MX2023011790A (es) | Terapias combinadas para tratar el cancer. | |
| MX2024002857A (es) | Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. | |
| IL312509A (en) | BAG3 methods and uses for treating inflammation | |
| MX2020002147A (es) | Composiciones útiles para la mejora del dolor. |